10x Genomics Inc-class A (TXG) Institutional Ownership & 13F Filings (Q2 2026)

TXG ranks #1569 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

TXG is a disclosed holding of Cathie Wood (ARK Investment Management), one of the tracked superinvestors on AlphaSMO — it makes up 2.5% of that fund's own 13F portfolio.

TXG is a top-conviction position for Blue Water Life Science Advisors, LP — at 15.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in TXG belongs to FMR LLC, but the position matters far more to Blue Water Life Science Advisors, LP, who has 15.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its TXG position for two straight quarters, increasing it by $481.5M to reach $675.9M today.

Two Sigma Investments, LP has trimmed its TXG position for two straight quarters, cutting it by $13.4M while still holding $5.4M.

TXG is down 5.1% today, but institutions show net buying of $446.8M this quarter — a divergence between today's price move and the underlying institutional flow.

TXG reported a net loss of $75.1M over the trailing twelve months.

• Not yet profitable — net loss of $75.1M over the trailing twelve months
• Revenue declined 4.3% year over year
• Net income improved year over year, from -$84.6M to -$75.1M
• Generated $136.1M in positive operating cash flow
• Current ratio of 4.46x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.31x equity — within a conventional range